Evaluating Ademetionine for Treatment of Obstructive Hypertrophic Cardiomyopathy A Multicenter, Double-Blind, Randomized Phase 2 Study

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Ademetionine in adults with obstructive hypertrophic cardiomyopathy oHCM through a multicenter, double-blind, randomized controlled Phase 2 trial. The study aims to understand how Ademetionine affects exercise capacity, heart failure symptoms, heart structure and function, and quality of life in this patient group. Participants will be randomly assigned to receive either Ademetionine or a placebo. The treatment period lasts 16 weeks, during which participants will have follow-up visits every 4 weeks. The study compares the effects of Ademetionine with placebo while monitoring safety and tolerability. Throughout the study, participants undergo assessments including cardiopulmonary exercise testing CPET, evaluations of heart function by echocardiography, and quality of life questionnaires. Researchers will closely monitor changes from baseline to Week 16 in exercise capacity and heart function, as well as adverse events. The total study duration for each participant is 16 weeks from baseline.

Ademetionine in Obstructive Hypertrophic Cardiomyopathy